CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025
CRISPR Therapeutics (NASDAQ: CRSP) has been named to TIME's 100 Most Influential Companies list for 2025 in the Pioneers category. The recognition highlights the company's groundbreaking work in gene editing and its expansion beyond treating sickle cell disease and beta thalassemia into cardiovascular and autoimmune diseases.
The selection process involved TIME editors evaluating companies based on impact, innovation, ambition, and success, with input from global contributors, correspondents, and external experts. CEO Samarth Kulkarni emphasized the company's mission to transform medicine through science and innovation, viewing the recognition as validation of their team's dedication to advancing genetic medicine.
CRISPR Therapeutics (NASDAQ: CRSP) è stata inserita nella lista delle 100 aziende più influenti del 2025 di TIME, nella categoria Pionieri. Questo riconoscimento mette in luce il lavoro rivoluzionario dell'azienda nell'editing genetico e la sua espansione oltre il trattamento della anemia falciforme e beta talassemia, includendo malattie cardiovascolari e autoimmuni.
Il processo di selezione ha coinvolto gli editori di TIME che hanno valutato le aziende in base all'impatto, innovazione, ambizione e successo, con il contributo di collaboratori globali, corrispondenti ed esperti esterni. Il CEO Samarth Kulkarni ha sottolineato la missione dell'azienda di trasformare la medicina attraverso la scienza e l'innovazione, considerando questo riconoscimento come una conferma della dedizione del loro team nel progresso della medicina genetica.
CRISPR Therapeutics (NASDAQ: CRSP) ha sido incluida en la lista de las 100 empresas más influyentes de TIME para 2025 en la categoría de Pioneros. Este reconocimiento destaca el trabajo innovador de la compañía en edición genética y su expansión más allá del tratamiento de la anemia falciforme y beta talasemia hacia enfermedades cardiovasculares y autoinmunes.
El proceso de selección involucró a los editores de TIME evaluando las empresas según su impacto, innovación, ambición y éxito, con aportes de colaboradores globales, corresponsales y expertos externos. El CEO Samarth Kulkarni enfatizó la misión de la empresa de transformar la medicina mediante la ciencia y la innovación, viendo este reconocimiento como una validación de la dedicación de su equipo para avanzar en la medicina genética.
CRISPR Therapeutics (NASDAQ: CRSP)가 2025년 TIME 선정 ‘가장 영향력 있는 100대 기업’ 중 개척자 부문에 이름을 올렸습니다. 이 상은 유전자 편집 분야에서 혁신적인 성과와 겸상적혈구 빈혈 및 베타 지중해빈혈 치료를 넘어 심혈관 및 자가면역 질환 분야로 확장한 점을 인정한 것입니다.
선정 과정은 TIME 편집진이 영향력, 혁신성, 야망, 성공을 기준으로 전 세계 기고자, 특파원, 외부 전문가의 의견을 반영해 기업을 평가했습니다. CEO 사마스 쿨카르니는 과학과 혁신을 통해 의학을 변화시키는 회사의 사명을 강조하며, 이번 수상을 유전 의학 발전을 위해 헌신하는 팀의 노력을 인정받는 것이라고 말했습니다.
CRISPR Therapeutics (NASDAQ : CRSP) a été nommé dans la liste des 100 entreprises les plus influentes de TIME pour 2025, dans la catégorie Pionniers. Cette reconnaissance met en avant le travail révolutionnaire de l'entreprise dans l'édition génétique et son expansion au-delà du traitement de la drépanocytose et de la bêta-thalassémie vers les maladies cardiovasculaires et auto-immunes.
Le processus de sélection a impliqué les rédacteurs de TIME évaluant les entreprises selon leur impact, innovation, ambition et succès, avec la contribution de collaborateurs mondiaux, correspondants et experts externes. Le PDG Samarth Kulkarni a souligné la mission de l'entreprise de transformer la médecine grâce à la science et à l'innovation, voyant cette reconnaissance comme une validation de l'engagement de leur équipe à faire progresser la médecine génétique.
CRISPR Therapeutics (NASDAQ: CRSP) wurde in die Liste der 100 einflussreichsten Unternehmen von TIME für 2025 in der Kategorie Pioniere aufgenommen. Die Auszeichnung würdigt die bahnbrechende Arbeit des Unternehmens im Bereich der Genomeditierung und seine Erweiterung über die Behandlung von Sichelzellanämie und Beta-Thalassämie hinaus auf Herz-Kreislauf- und Autoimmunerkrankungen.
Der Auswahlprozess umfasste die Bewertung durch TIME-Redakteure anhand von Einfluss, Innovation, Ehrgeiz und Erfolg, unter Einbeziehung von globalen Beiträgern, Korrespondenten und externen Experten. CEO Samarth Kulkarni betonte die Mission des Unternehmens, die Medizin durch Wissenschaft und Innovation zu transformieren, und sieht die Auszeichnung als Bestätigung des Engagements ihres Teams für den Fortschritt der Genmedizin.
- None.
- None.
ZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, has been named to the fifth annual TIME 100 Most Influential Companies list. The Company was recognized in the Pioneers category for its groundbreaking work in advancing the field of gene editing.
TIME highlighted CRISPR Therapeutics’ expansion beyond its landmark success in treating sickle cell disease and beta thalassemia, noting the Company’s progress into diseases with significant unmet medical need such as cardiovascular and autoimmune diseases. This momentum reflects CRISPR Therapeutics’ broader vision to make genetic medicine more scalable and accessible for patients worldwide.
“Since our founding, CRISPR Therapeutics has been driven by a mission to transform medicine through bold science and meaningful innovation,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “We are honored to be recognized by TIME. This acknowledgement is testament to the extraordinary dedication and collaboration across our teams to pioneer the next frontier of genetic medicine and improve the lives of patients around the world.”
To select the list of the world's most influential businesses of the year, TIME editors requested nominations across sectors, surveyed its global network of contributors and correspondents around the world, and sought advice from outside experts. They evaluated each company on key factors, including impact, innovation, ambition, and success. The result is a diverse group of organizations shaping the future of business and society.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
Why was CRISPR Therapeutics named to TIME's Most Influential Companies list in 2025?
What areas is CRISPR Therapeutics (NASDAQ: CRSP) expanding into beyond sickle cell disease?
Who is the CEO of CRISPR Therapeutics in 2025?
How did TIME select CRISPR Therapeutics for its Most Influential Companies list?
